3Ibarra M, Wu S, Murayama K, et al. Malignant Hyperthermia in Japan:Mutation Screening of the Entire Ryanodine Receptor Type 1 Gene Coding Region by Direct Sequencing[ J ]. Anesthesiology, 2006, 104(6):1146-1154.
4Hommertzheim R, Steinke E E. Malignant Hyperthermia-the Perioperative Nurse's Role[J]. AORN J,2006, 83(1):149-164.
6McCarthy TV,Quane KA, Lynch PJ. Ryanodine receptor mutations in malignant hyperthermia and central core disease. Hum Mutat, 2000,15: 410-417.
7Zhao F, Li P, Chen SR, et al. Dantrolene inhibition of ryanodine receptor Ca2+ release channels. Molecular mechanism and isoform selectivity. J Biol Chem, 2001, 276:13810-13816.
8Nicole M, Renee KH,Payen JF,et al. Presence of two different genetic traits in malignant hyperthermia families: implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility. Anesthesiology, 2002, 97 : 1067-1074.
9Girad T, Treves S, Voronkov E, et al. Molecular genetic testing of malignant hyperthermia susceptibility. Anesthesiology, 2004, 100: 1076- 1080.
10Robison R, Hopkins P, Carsana A, et al. Several interacting genes influence the malignant hyperthermia phenotype. Hum Genet, 2003, 112: 217-218.
8Ibarra MA, Wu S, Murayama K, et al. Malignant hyperthermia in Ja- pan:Mutation Screening of the Entire Ryanodine Receptor Type 1 Gene Coding Region by Direct Sequencing [ J ]. Anesthersiology, 2006,104(6) :1146 - 1154.
9Ben Abram R, Adnet P, Glauber V, et al. Malignant hyperthermia [J]. Postgxad Med J,1998,74(867) :11 - 17.
10Harrison G. Dosage of dantrolene: "empiric" please ! [ J ]. Anaesth Intensive Care,2003,31 ( 1 ) : 122.
